Stockscreener 앱 받기
1.52
2.70%
0.04
시간 외 거래:
1.49
-0.03
-1.97%
전일 마감가:
$1.48
열려 있는:
$1.44
하루 거래량:
4.11M
Relative Volume:
0.80
시가총액:
$175.12M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.4578
EPS:
-3.32
순현금흐름:
$-175.17M
1주 성능:
-5.59%
1개월 성능:
+38.18%
6개월 성능:
-6.17%
1년 성능:
-21.65%
1일 변동 폭
$1.40
$1.54
1주일 범위
$1.40
$1.75
52주 변동 폭
$0.6603
$3.70
Coherus Biosciences Inc Stock (CHRS) Company Profile
명칭
Coherus Biosciences Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
1.52 | 175.12M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-11-17 | 개시 | Robert W. Baird | Outperform |
| 2023-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St
Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire
Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat
California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN
Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board - Investing.com
Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider
Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Coherus Biosciences Announces Board Member Resignation - TipRanks
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia
Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP
Accord acquires Coherus’ Udenyca business - The Pharma Letter
Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers
Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights
S&P 500 Total Return (TCM23) Quote - The Globe and Mail
Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues
Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
Redwood City-based Coherus' stock surges after major drug sale - The Business Journals
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive
Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma
Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa
Coherus shares surge on $558M Udenyca divestiture deal - Investing.com
Unusually active option classes on open December 3rd - TipRanks
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl
Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks
Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM
Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals - MarketWatch
Coherus Biosciences Sells UDENYCA Franchise to Intas - TipRanks
Coherus BioSciences inks $558.4M deal with Intas Pharmaceuticals; shares rally - Investing.com
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M (NASDAQ:CHRS) - Seeking Alpha
Coherus Biosciences to sharpen fcous on immuno-oncology portfolio - TipRanks
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - GlobeNewswire
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas - The Bakersfield Californian
CHRS (Coherus BioSciences) 50-Day SMA : $0.92 (As of Nov. 30, 2024) - GuruFocus.com
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - The Manila Times
Coherus BioSciences to Present at Citi Healthcare Conference's Oncology Panel | CHRS Stock News - StockTitan
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - GuruFocus.com
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Coherus Biosciences Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):